<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894656</url>
  </required_header>
  <id_info>
    <org_study_id>21-000771</org_study_id>
    <nct_id>NCT04894656</nct_id>
  </id_info>
  <brief_title>Intestinal Permeability and Gastroparesis</brief_title>
  <official_title>Assessing Intestinal Barrier Function and Permeability in Patients With Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate potential mechanisms that could lead to the&#xD;
      development of a condition known as gastroparesis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess duodenal epithelial tight junction structure in GP patients using confocal laser endomicroscopy.</measure>
    <time_frame>through study completion, approximately 3-4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess small intestinal permeability using the lactulose:mannitol urinary excretion test.</measure>
    <time_frame>through study completion, approximately 3-4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure serum levels of immune markers (e.g., IL-1,4,6,10,12,13,18; zonulin, CRP, TNF-alpha, tryptase,) in GP patients and compare to healthy controls.</measure>
    <time_frame>One time measurement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitate different duodenal cell types (e.g., mast cells (CK117), eosinophils, enterochromaffin, intraepithelial lymphocytes (IELs) and CCK-containing cells) in patients with GP using biopsies from both the D1 and D2 duodenal segments.</measure>
    <time_frame>through study completion, approximately 3-4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the relationship of GP symptoms to intestinal permeability, using validated questionnaires, and to histopathological changes.</measure>
    <time_frame>through study completion, approximately 3-4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Gastroparesis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy</intervention_name>
    <description>Tests to assess intestinal permeability</description>
    <arm_group_label>Gastroparesis patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18-75 years old).&#xD;
&#xD;
          -  Men and women.&#xD;
&#xD;
          -  Patients with gastroparesis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if symptoms are thought to represent an&#xD;
             organic disorder (e.g., peptic ulcer disease, hepatitis, pancreatitis, inflammatory&#xD;
             bowel disease, a known malignancy, radiation-induced injury, an active infection,&#xD;
             vasculitis, celiac disease), GERD, esophagitis, eosinophilic esophagitis or H. pylori.&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus (hemoglobin A1C &gt; 10).&#xD;
&#xD;
          -  Patients with prior surgery to the esophagus, stomach or duodenum.&#xD;
&#xD;
          -  Patients taking opioids, steroids, anti-histamines, immunosuppressive agents, NSAIDs,&#xD;
             or mast cell stabilizing agents within the prior 3 months.&#xD;
&#xD;
          -  Patients currently prescribed aspirin or aspirin regimens for other clinical reasons.&#xD;
&#xD;
          -  Patients with known allergies to lactulose: mannitol will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cangemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J Cangemi, MD</last_name>
      <phone>904-953-6970</phone>
      <email>cangemi.david@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>David J. Cangemi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

